Zai Lab Limited (FRA:1ZL)

Market Cap	1.91B -32.3%
Revenue (ttm)	376.40M +24.1%
Net Income	-176.27M
EPS	-1.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	16.70
Previous Close	16.70
Day's Range	16.70 - 16.70
52-Week Range	13.20 - 38.20
Beta	n/a
RSI	62.61
Earnings Date	Feb 26, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1ZL

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD